Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.65 |
| ▸ | NPC1 | O15118 | 9/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.65 |
| ▸ | HPGD | P15428 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | CASP1 | P29466 | 1/20 | 0.65 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7564852 | 0.89 | RAB9A (0.79) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL21059190 | 0.84 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL13387589 | 0.84 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL10192215 | 0.83 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL7564856 | 0.83 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL1699197 | 0.83 | SMN1; SMN2 (0.70) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL12411578 | 0.82 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL23484018 | 0.82 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL16374712 | 0.82 | NPC1 (0.69) | RAB9ANPC1SMN1; SMN2HPGDMAPT | |
| SCHEMBL13387474 | 0.81 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190105367-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2019-04-11 | — | — | US | disclosed |
| US-10155021-B2 | Antimicrobial 4-oxoquinolizines | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-20170232060-A9 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170106045-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2017-04-20 | — | — | US | disclosed |
| US-9403818-B2 | Antimicrobial 4-oxoquinolizines | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2670410-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Evolva SA (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-20130252882-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EVOLVA SA (CH) | 2013-09-26 | — | — | US | disclosed |
| WO-2012104305-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EVOLVA SA (CH) | 2012-08-09 | — | — | WO | disclosed |
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105367-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | RAB9A 1963/4885NPC1 1403/4885SMN1; SMN2 4640/4885 |
| US-10155021-B2 | Antimicrobial 4-oxoquinolizines | DCAF15, CUL4A, CUL4B | RAB9A 1925/4885NPC1 1377/4885SMN1; SMN2 4656/4885 |
| US-20170106045-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | RAB9A 1963/4885NPC1 1403/4885SMN1; SMN2 4640/4885 |
| US-20170232060-A9 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | RAB9A 1963/4885NPC1 1403/4885SMN1; SMN2 4640/4885 |
| US-20130252882-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | RAB9A 1963/4885NPC1 1403/4885SMN1; SMN2 4640/4885 |
| US-20110021473-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | PDE4A, PDE4B, PDE4C | RAB9A 322/4885NPC1 4088/4885SMN1; SMN2 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.